Cardiovascular: Cardiomyopathy Circulatory System Cardiomyopathy
Conditions
Interventions
Eplerenone vs placebo
Sponsors
Record Provided by the NHSTCT Register - 2007 Update - Department of Health
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Stable patients with an established diagnosis of cardiomyopathy as assessed by history, examination and typical ECG/Echo findings who are on maximally tolerated doses of appropriate drugs with no changes being made to the prescription in the 2 months preceding the start of the trial.
Exclusion criteria
Exclusion criteria: 1. Patients already established on treatment with an aldosterone antagonist 2. Patients with contraindications to eplerenone (hyperkalaemia, renal failure) 3. Critically ill patients requiring respiratory and/or circulatory support 4. Pacemaker or ICD 5. Implanted ferromagnetic cerebrovascular clips 6. Pregnant women (precautionary only) 7. Intolerance of confined spaces 8. Inability to lie supine for 60 minutes 9. Unwilling or unable to give written informed consent 10.Atrial fibrillation or ventricular bigeminy 11. Any contraindication to CMR. 12. Recent MI 13. HCM patients who have received surgical/alcohol ablation treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in amount of fibrosis as determined by CMR Late enhancement | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Improvement in myocardial oxygen consumption (MVO2) 2. Reduction in major adverse cardiovascular events | — |
Countries
United Kingdom
Outcome results
None listed